Nathan I Comeaux
Overview
Explore the profile of Nathan I Comeaux including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
413
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chang J, Xu X, Shroff G, Comeaux N, Li W, Rodon Ahnert J, et al.
J Immunother Cancer
. 2024 Oct;
12(10).
PMID: 39384194
Background: BMS-986156 is an agonist of the glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR) and promotes increased effector T-cell activation. Combined anti-GITR, anti-programmed death-1, anti-cytotoxic T-lymphocyte-associated protein 4 antibodies...
2.
He K, Hong D, Tang C, Sezen D, Cox L, Maleki A, et al.
Radiother Oncol
. 2023 Mar;
183:109618.
PMID: 36921766
Purpose: Ipilimumab plus stereotactic ablative radiotherapy (SABR) demonstrate satisfactory short-term clinical benefit and low toxicities in metastatic cancers. Here, we report the 5-year overall survival (OS) rates for patients with...
3.
Barsoumian H, Ramapriyan R, Younes A, Caetano M, Menon H, Comeaux N, et al.
J Immunother Cancer
. 2020 Oct;
8(2).
PMID: 33106386
Background: Despite some successes with checkpoint inhibitors for treating cancer, most patients remain refractory to treatment, possibly due to the inhibitory nature of the tumor stroma that impedes the function...
4.
Theelen W, Chen D, Verma V, Hobbs B, Peulen H, Aerts J, et al.
Lancet Respir Med
. 2020 Oct;
9(5):467-475.
PMID: 33096027
Background: Radiotherapy might augment systemic antitumoral responses to immunotherapy. In the PEMBRO-RT (phase 2) and MDACC (phase 1/2) trials, patients with metastatic non-small-cell lung cancer were randomly allocated immunotherapy (pembrolizumab)...
5.
Welsh J, Menon H, Chen D, Verma V, Tang C, Altan M, et al.
J Immunother Cancer
. 2020 Oct;
8(2).
PMID: 33051340
Background: In this phase I/II trial, we evaluated the safety and effectiveness of pembrolizumab, with or without concurrent radiotherapy (RT), for lung and liver lesions from metastatic non-small cell lung...